Trials / Completed
CompletedNCT00219544
Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic peripheral Neuropathy and Postherpetic Neuralgia).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin (Lyrica) | pregabalin 150mg/day (75mg BID) |
| DRUG | Pregabalin (Lyrica) | pregabalin 300 mg/day (150mg BID) |
| DRUG | Pregabalin (Lyrica) | pregabalin 600/day (300mg BID) |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2005-09-22
- Last updated
- 2021-01-22
- Results posted
- 2009-06-02
Locations
30 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00219544. Inclusion in this directory is not an endorsement.